Study wrapper · #599
Improvement of cardiomyocyte function by in vivo hexarelin treatment in streptozotocin-induced diabetic rats.
Editor's note
In streptozotocin-induced diabetic rats, researchers isolated heart-muscle cells and reported that hexarelin, a synthetic growth hormone-releasing peptide given for two weeks, reversed several features of diabetic cardiomyocyte dysfunction: it improved cell contraction and relaxation, restored calcium-handling and a prolonged electrical (action-potential) duration toward normal, upregulated the GHS receptor, and shifted apoptosis-related proteins in an anti-cell-death direction. The single-cell electrophysiology gives the mechanism unusual granularity, but the work remains a single chemically induced diabetes model with small numbers, and isolated-cell findings do not guarantee whole-heart or clinical benefit. These are preclinical findings; human data are needed before any clinical conclusions can be drawn.
Plain-language abstract
Researchers studied hexarelin, a lab-made peptide, in rats made diabetic with a chemical. After two weeks of hexarelin injections, they isolated individual heart-muscle cells and measured how they worked. Diabetic rats' heart cells contracted and relaxed poorly and had disrupted calcium handling and abnormal electrical activity. Hexarelin treatment reversed these problems, bringing contraction, calcium handling, and electrical behavior back toward normal. It also increased the cell receptor it acts through and shifted several proteins away from a cell-death pattern. The authors conclude hexarelin improved diabetic heart-cell function through these mechanisms. The abstract reports no adverse events. These are preclinical findings in rats; human research would be needed before drawing clinical conclusions.